To develop and commercialize novel, first-in-class therapeutics that meaningfully improve the lives of patients with kidney and vascular diseases.
To become a recognized leader in healthcare innovation and a trusted partner to the kidney and vascular communities.
Seek regulatory approval for vonapanitase and commercialize directly in the United States
Partner vonipanitase outside of the United States
Continue development of vonapanitase for additional indications
Build a pipeline of novel therapeutics in kidney and vascular diseases
Timothy Noyes is a veteran biotech leader with deep experience in growing companies and bringing innovative therapies to market. He has served as President, Chief Executive Officer and member of the board of directors at Proteon since 2006. Prior joining Proteon, he was the Chief Operating Officer of Trine Pharmaceuticals from 2002 to 2006 and held several management positions with GelTex Pharmaceuticals prior to its acquisition by Genzyme. After the acquisition, from 2001 to 2002, he held the positions of President, Renal Division and President, GelTex Pharmaceuticals. Earlier in his career, Tim also spent several years at Merck, serving in multiple roles in its hypertension and heart failure group and managed care division. Tim received his A.B. from Harvard College and an M.B.A. from Harvard Business School.
George Eldridge’s financial background and expertise spans multiple industries, including biotechnology and investment banking. At Proteon, George has served as chief financial officer since 2013. From 2009 to 2013, he served as a consultant to companies in the biotech industry, acting as a Chief Financial Officer and providing advisory services. Prior to that, he held the roles of Chief Financial Officer at Targanta Therapeutics, Therion Biologics, Curis (previously Ontogeny) and Boston Life Sciences. George has also worked as an investment banker at Kidder Peabody. He holds a B.A. from Dartmouth College and an M.B.A. from the University of Chicago.